Finally, the immunosuppressive effects of checkpoint receptor expression have been targeted by antibody-mediated blockade of PD-1/PD-L1 interactions; this blockade restored IFN-γ release and augmented anti-tumor activity of iNKTs (37, 54, 56–58). The gene discussed is IFNG; the disease is neoplasm.